Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
6.67
+0.27 (4.22%)
At close: Aug 7, 2026, 4:00 PM EDT
6.70
+0.03 (0.45%)
After-hours: Aug 7, 2026, 7:34 PM EDT

Gyre Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
119.38116.59105.76113.45102.297.34
Revenue Growth
13.53%10.24%-6.78%10.91%1293.98%-82.48%
Gross Profit
112.58111.17101.87108.8197.5-0.04
Operating Income
-16.6811.4916.16-67.239.2-87.89
Net Income
-18.475.0312.09-92.932.3-87.93
Earnings Per Share
-0.210.020.05-1.410.030.24
EPS Growth
--60.00%---87.50%-

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
74.852.4326.6733.5125.1846.85
Total Debt
3.420.941.60.410.612.39
Net Cash (Debt)
71.3851.4925.0733.124.5644.47
Net Cash Growth
34.75%105.34%-24.25%34.76%-44.76%-42.78%
Net Cash Per Share
0.740.500.250.500.320.67

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-19.241.01-3.6425.8910.68-83.76
Capital Expenditures
-1.25-1.19-2.32-8.52-4.99-0.84
Free Cash Flow
-20.49-0.18-5.9617.385.69-84.59
Free Cash Flow Growth
---205.25%--

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
94.30%95.35%96.33%95.91%95.31%-0.57%
Operating Margin
-13.97%9.85%15.28%-59.26%9.00%-1197.79%
Pretax Margin
-13.49%12.38%21.95%-67.84%9.20%-1198.32%
Profit Margin
-11.95%8.47%16.92%-75.35%4.22%-1198.32%
FCF Margin
-17.16%-0.15%-5.63%15.32%5.56%-1152.82%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-353.00242.00-265.0056.88
Forward PE
-32.84----
P/FCF Ratio
230.15--113.2588.81-
PS Ratio
6.445.539.8717.344.943.89